FDA

New orphan drug (clobazam-Onfi) approved for Lennox-Gastaut seizures

young girl climbing wall  Some types of seizures are difficult to control. This is certainly true of Lennox-Gastaut syndrome. the FDA has approved cobazam (Onfi) as add-on therapy to treat seizures in children 2 years or older and adults.

Approval Date: 
Mon, 10/24/2011
Company: 
Lundbeck

The Essential Guide to Medical News (Overcoming Osteoporosis)

Osteoporosis risk, prevention and new treatment
$3.99

Have you overdrawn your bone bank and ended up with osteoporosis? Find out about Prolia (denosumab), a strong new medicine for weak bones. See if you have any of the 5 crucial risk factors that can lead to brittle bones, know how much calcium you really need each day and meet our guest editor, Dr. Mary Bouxsein from Harvard. Six detail packed pages in this easy to understand newsletter.

 

Comb-Bound Booklet.

$3.99

Expert committee recommends Avastin (bevacizumab) FDA approval for breast cancer be revoked

people with backs turned  An expert panel voted unanimously to remove the FDA approval for Bavacizumab (Avastin) in treatment of breast cancer.

Lipitor, Zocor and Pravachol in high doses appear to pose increased risk of diabetes

man at desk thinking Two years ago, what researchers call a “signal of risk” was identified for one member of the cholesterol lowering drugs known as statins (what your doctor would call HMG-Co-A reductase inhibitors) app

Members Only: 

man at desk thinking Two years ago, what researchers call a “signal of risk” was identified for one member of the cholesterol lowering drugs known as statins (what your doctor would call HMG-Co-A reductase inhibitors) appeared in the JUPITER study for Crestor (rosuvastatin) [Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statins trails. Lancet 2010; 375:735-742]. What this meant was that Crestor appeared to be associated with about a 9% increased risk of diabetes.

A new study being presented at the American Diabetes Association-ADA meeting (Preiss D, Sesshasai, SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared to moderate-dose statin therapy. JAMA 2011; 305:2556-2564) looked at 32,752 people. The studies reviewed included A to Z, IDEAL, PROVE-IT, SEARCH and TNT. What this new analysis found was that high dose statin use (Lipitor-Atorvastatin, Pravachol-pravastatin and Zocor-simvastatin) appears to carry roughly a 12% increased diabetes risk. It is crucial to remember that overall, the benefits (avoiding heart disease and heart attack, etc.) outweigh the risk of diabetes for this family of medicines.

members circle The studies reviewed looked at Lipitor, Pravachol and Zocor. Prove IT compared 40 mg of Pravachol to 80 mg of Lipitor in 4,162 people. A to Z had a more complicated format, but looked at a given time of Zocor 40 mg then changed to 80 mg of Zocor in some patients. Other patients received 4 months of dietary counseling and placebo followed by 20 mg of Zocor for roughly 4,500 people. TNT was a large study of 15,464 people and involved treating to new targets and compared 80 mg of Lipitor to 10 mg of Lipitor. IDEAL looked at 8,888 people after a heart attack and compared 80 mg of Lipitor to 20 mg of Zocor. Finally, SEARCH looked at 80 mg of Zocor compared to 20 mg of Zocor and also tried to sort out the role of folic acid and vitamin B 12

As always, talk to your doctor about any questions regarding your medicines BEFORE you make any changes in your treatments. Visit Amazon author central:

http://www.amazon.com/James-J.-Rybacki/e/B000APKNZM to find the EGPD update on statins and cholesterol with recommendations about diabetes testing and statin use.

Yervoy (ipilimumab) approved for melanoma by the FDA

sears tower  A medicine which first received notariety at the American Society of Clinical Oncologists (ASCO) this summer was approved by the FDA today. This drug is the first in a new family of medicines called anti-CTLA 4 inhibitors.

Approval Date: 
Fri, 03/25/2011
Company: 
Bristol-Myers squibb

Waiting for weight loss and Contrave

woman with blue face Are you getting blue in the face waiting for a new prescription weight loss drug? Today may be your day. The expert advisory committee of the FDA (Endocrine and Metabolic) recommended that the FDA approve Contrave.

Approval Date: 
Mon, 01/31/2011
Company: 
Orexigen

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.